Global Perspectives on Cystic Fibrosis: Trials, Therapies, and the Road Ahead

*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" tabindex="-1" data-turn-id= "request-WEB:999cd22f-377a-429b-92bd-84de1f700f39-1" data-testid= "conversation-turn-4" data-scroll-anchor="true" data-turn= "assistant">   *]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" tabindex="-1" data-turn-id= "request-WEB:999cd22f-377a-429b-92bd-84de1f700f39-1" data-testid= "conversation-turn-4" data-scroll-anchor="true" data-turn= "assistant"> In this third and final deep-dive episode, Nicholas Simmonds highlights the importance of collaborative networks, such as the European Cystic Fibrosis Society (ECFS) Clinical Trials Network, in enabling global clinical trials. He also emphasises the central role of the patient voice in developing new therapies, using CFTR modulators as a key example. Timestamps: 00:00 – Introduction 00:55 – ECFS Network 03:29 – Trial design 04:54 – Therapy frontiers 07:48 – Curative approaches 13:07 – Clinician message